HCW Biologics (NASDAQ:HCWB) Posts Earnings Results

HCW Biologics (NASDAQ:HCWB) posted its quarterly earnings data on Tuesday. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.18), FiscalAI reports. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $7.01 million.

HCW Biologics Price Performance

NASDAQ:HCWB traded down $0.00 during trading hours on Tuesday, reaching $0.36. 394,144 shares of the company were exchanged, compared to its average volume of 25,039,006. The firm has a market cap of $1.27 million, a price-to-earnings ratio of -0.03 and a beta of 0.79. HCW Biologics has a 52-week low of $0.34 and a 52-week high of $17.80. The stock has a 50 day simple moving average of $0.77 and a 200 day simple moving average of $2.04.

Institutional Trading of HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC bought a new stake in HCW Biologics Inc. (NASDAQ:HCWB) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics at the end of the most recent quarter. 2.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $35.00.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.